These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 17276063)

  • 41. Pharmacokinetic, pharmacodynamic, and efficacy profiles of alogliptin, a novel inhibitor of dipeptidyl peptidase-4, in rats, dogs, and monkeys.
    Lee B; Shi L; Kassel DB; Asakawa T; Takeuchi K; Christopher RJ
    Eur J Pharmacol; 2008 Jul; 589(1-3):306-14. PubMed ID: 18538760
    [TBL] [Abstract][Full Text] [Related]  

  • 42. 3-[2-((2S)-2-cyano-pyrrolidin-1-yl)-2-oxo-ethylamino]-3-methyl-butyramide analogues as selective DPP-IV inhibitors for the treatment of type-II diabetes.
    Coumar MS; Chang CN; Chen CT; Chen X; Chien CH; Tsai TY; Cheng JH; Wu HY; Han CH; Wu SH; Huang YW; Hsu T; Hsu LJ; Chao YS; Hsieh HP; Jiaang WT
    Bioorg Med Chem Lett; 2007 Mar; 17(5):1274-9. PubMed ID: 17194587
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Design and synthesis of new potent dipeptidyl peptidase IV inhibitors with enhanced ex vivo duration.
    Kondo T; Nekado T; Sugimoto I; Ochi K; Takai S; Kinoshita A; Tajima Y; Yamamoto S; Kawabata K; Nakai H; Toda M
    Bioorg Med Chem; 2007 Apr; 15(7):2631-50. PubMed ID: 17293118
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Pyrrolidine-5,5-trans-lactams. 2. The use of X-ray crystal structure data in the optimization of P3 and P4 substituents.
    Andrews DM; Chaignot H; Coomber BA; Good AC; Hind SL; Johnson MR; Jones PS; Mills G; Robinson JE; Skarzynski T; Slater MJ; Somers DO
    Org Lett; 2002 Dec; 4(25):4479-82. PubMed ID: 12465917
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Dipeptidyl peptidase-IV inhibitors: a major new class of oral antidiabetic drug.
    Idris I; Donnelly R
    Diabetes Obes Metab; 2007 Mar; 9(2):153-65. PubMed ID: 17300591
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A novel dipeptidyl peptidase-4 inhibitor, alogliptin (SYR-322), is effective in diabetic rats with sulfonylurea-induced secondary failure.
    Asakawa T; Moritoh Y; Kataoka O; Suzuki N; Takeuchi K; Odaka H
    Life Sci; 2009 Jul; 85(3-4):122-6. PubMed ID: 19427871
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Discovery of beta-homophenylalanine based pyrrolidin-2-ylmethyl amides and sulfonamides as highly potent and selective inhibitors of dipeptidyl peptidase IV.
    Nordhoff S; Cerezo-Gálvez S; Deppe H; Hill O; López-Canet M; Rummey C; Thiemann M; Matassa VG; Edwards PJ; Feurer A
    Bioorg Med Chem Lett; 2009 Aug; 19(15):4201-3. PubMed ID: 19515557
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Newly approved and promising antidiabetic agents.
    Combettes M; Kargar C
    Therapie; 2007; 62(4):293-310. PubMed ID: 17983555
    [TBL] [Abstract][Full Text] [Related]  

  • 49. ASP4,000, a novel, selective, dipeptidyl peptidase 4 inhibitor with antihyperglycemic activity.
    Tanaka-Amino K; Matsumoto K; Hatakeyama Y; Shima I; Takakura S; Muto S
    Eur J Pharmacol; 2008 Aug; 590(1-3):444-9. PubMed ID: 18582861
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Dipeptide boronic acid inhibitors of dipeptidyl peptidase IV: determinants of potency and in vivo efficacy and safety.
    Connolly BA; Sanford DG; Chiluwal AK; Healey SE; Peters DE; Dimare MT; Wu W; Liu Y; Maw H; Zhou Y; Li Y; Jin Z; Sudmeier JL; Lai JH; Bachovchin WW
    J Med Chem; 2008 Oct; 51(19):6005-13. PubMed ID: 18783201
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A triumph for physiology driving drug discovery: the potential impact of dipeptidyl peptidase-IV inhibitors in type 2 diabetes.
    Donnelly R
    Diabetes Obes Metab; 2007 Mar; 9(2):151-2. PubMed ID: 17300590
    [No Abstract]   [Full Text] [Related]  

  • 52. Diprolyl nitriles as potent dipeptidyl peptidase IV inhibitors.
    Zhao G; Taunk PC; Magnin DR; Simpkins LM; Robl JA; Wang A; Robertson JG; Marcinkeviciene J; Sitkoff DF; Parker RA; Kirby MS; Hamann LG
    Bioorg Med Chem Lett; 2005 Sep; 15(18):3992-5. PubMed ID: 16046120
    [TBL] [Abstract][Full Text] [Related]  

  • 53. 4-aminophenylalanine and 4-aminocyclohexylalanine derivatives as potent, selective, and orally bioavailable inhibitors of dipeptidyl peptidase IV.
    Duffy JL; Kirk BA; Wang L; Eiermann GJ; He H; Leiting B; Lyons KA; Patel RA; Patel SB; Petrov A; Scapin G; Wu JK; Thornberry NA; Weber AE
    Bioorg Med Chem Lett; 2007 May; 17(10):2879-85. PubMed ID: 17350841
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A new screening method based on yeast-expressed human dipeptidyl peptidase IV and discovery of novel inhibitors.
    Hu CX; Huang H; Zhang L; Huang Y; Shen ZF; Cheng KD; Du GH; Zhu P
    Biotechnol Lett; 2009 Jul; 31(7):979-84. PubMed ID: 19267232
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The reversed binding of beta-phenethylamine inhibitors of DPP-IV: X-ray structures and properties of novel fragment and elaborated inhibitors.
    Nordhoff S; Cerezo-Gálvez S; Feurer A; Hill O; Matassa VG; Metz G; Rummey C; Thiemann M; Edwards PJ
    Bioorg Med Chem Lett; 2006 Mar; 16(6):1744-8. PubMed ID: 16376544
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The role of vildagliptin in the management of type 2 diabetes mellitus.
    Kleppinger EL; Helms K
    Ann Pharmacother; 2007 May; 41(5):824-32. PubMed ID: 17456545
    [TBL] [Abstract][Full Text] [Related]  

  • 57. 4-arylcyclohexylalanine analogs as potent, selective, and orally active inhibitors of dipeptidyl peptidase IV.
    Kaelin DE; Smenton AL; Eiermann GJ; He H; Leiting B; Lyons KA; Patel RA; Patel SB; Petrov A; Scapin G; Wu JK; Thornberry NA; Weber AE; Duffy JL
    Bioorg Med Chem Lett; 2007 Nov; 17(21):5806-11. PubMed ID: 17851076
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Pharmacodynamics of vildagliptin in patients with type 2 diabetes during OGTT.
    He YL; Wang Y; Bullock JM; Deacon CF; Holst JJ; Dunning BE; Ligueros-Saylan M; Foley JE
    J Clin Pharmacol; 2007 May; 47(5):633-41. PubMed ID: 17442688
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Dipeptidyl peptidase 4 inhibition and vildagliptin therapy for type 2 diabetes.
    Del Prato S
    Int J Clin Pract Suppl; 2007 Aug; (154):38-48. PubMed ID: 17593276
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Dipeptidyl peptidase-4 inhibitors: clinical data and clinical implications.
    Ahrén B
    Diabetes Care; 2007 Jun; 30(6):1344-50. PubMed ID: 17337494
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.